Akido 推出由 ScopeAI 驱动的首个 AI 原生医疗系统
Akido Unveils First AI-Native Health System Powered by ScopeAI
您需要了解的信息
Akido 宣布将其专有的 ScopeAI 技术扩展到 100 家诊所、虚拟护理业务和现场医疗服务，为加州、纽约市和罗德岛州的 100 万患者提供服务。
该公司从其公司名称中删除了“Labs”，更名为 Akido，并推出了“Akido Medical”作为其 AI 原生实体和数字诊所的品牌。
ScopeAI 在就诊期间通过组织实时临床信息并提供诊断辅助来运作，实现了五倍多的面对面患者参与度和净推荐值 96。
该技术通过 iPad 部署在洛杉矶街头医疗营地，实现了急诊科使用率降低 55%，同时当天获得护理的比例为 53%。
此次扩张得到了新技术领导团队的支持，包括前高盛副总裁 Matt Rothstein 和 Pearl 联合创始人 Cambron Carter，以及新成立的独立 AI 临床咨询委员会。
实时诊断预处理和 TAMSS 基准测试
Akido 在 100 家诊所、虚拟护理网络和移动现场医疗单位中运营，为加州、纽约市和罗德岛州的 100 万受保人群提供护理服务。除了扩张之外，该组织还从其母公司名称中删除了“Labs”，并推出了 Akido Medical 作为其设施网络的临床品牌。
ScopeAI 作为一种环境临床智能引擎运作，将原始就诊对话转化为结构化诊断框架：
环境调查式接诊：在患者就诊期间持续倾听，整理分散的患者病史、症状和临床数据，为医生提供即时的诊断先机。
街头医疗现场部署：部署在洛杉矶营地的 iPad 上，为缺乏既往病历的无家可归人群提供持续护理。
TAMSS 压力测试框架：使用总可寻址医疗情境空间（TAMSS）基准对 203,000 次真实世界就诊进行评估，以确保模型在复杂慢性病和自发的患者陈述中的准确性。
强化工程基础设施：由新任工程副总裁 Matt Rothstein（曾任高盛和 NIH）和首席 AI 架构师 Cambron Carter（Pearl 联合创始人）领导。
“医生正在离开医学行业，因为系统要求他们每年用更少的资源做更多的事情，” Akido 首席执行官兼联合创始人 Prashant Samant 表示。“ScopeAI 减轻了就诊的管理负担，并支持调查式接诊，以便医生能够将时间花在只有人类医生才能做的事情上。”随着 Akido 在其多州诊所版图中扩展 Akido Medical，它为 AI 原生医疗系统将如何在全国范围内重新定义医疗可及性和医生执业提供了功能性蓝图。
What You Should Know Akido announced the expansion of its proprietary ScopeAI technology across 100 clinics, virtual care operations, and field medicine services, serving 1 million patients across California, New York City, and Rhode Island.
The company dropped “Labs” from its corporate name to become Akido and debuted “Akido Medical” as the brand for its AI-native physical and digital clinics.
ScopeAI
operates during visits by organizing real-time clinical pictures and providing diagnostic assistance, yielding five times more face-to-face patient engagement and a 96 Net Promoter Score.
Deployed in Los Angeles street medicine encampments via iPads, the technology achieved a 55% reduction in Emergency Department utilization alongside 53% same-day care access.
The expansion is backed by new technical leadership—including former Goldman Sachs VP Matt Rothstein and Pearl co-founder Cambron Carter—plus a newly formed independent AI Clinical Advisory Council.
Real-Time Diagnostic Pre-Processing and TAMSS Benchmarking
Operating across 100 clinics, virtual care networks, and mobile field medicine units, Akido provides care access to 1 million covered lives across California, New York City, and Rhode Island. Alongside the expansion, the organization dropped “Labs” from its parent name and launched Akido Medical as the clinical brand for its facility network.
ScopeAI
operates as an ambient clinical intelligence engine that transforms raw visit dialogue into structured diagnostic frameworks:
Ambient Investigative Intake:
Listens continuously during patient encounters, organizing scattered patient histories, symptoms, and clinical data to give physicians an immediate diagnostic head start.
Street Medicine Field Deployment:
Deployed on iPads in Los Angeles encampments to deliver continuous care to unhoused populations lacking prior medical records.
TAMSS Stress-Testing Framework:
Evaluated against 203,000 real-world encounters using the Total Addressable Medical Situation Space (TAMSS) benchmark to ensure model accuracy across complex chronic conditions and unscripted patient presentations.
Strengthened Engineering Infrastructure:
Led by newly appointed VP of Engineering Matt Rothstein (formerly of Goldman Sachs and NIH) and Principal AI Architect Cambron Carter (co-founder of Pearl).
“Doctors are leaving medicine because the system asks them to do more with less every year,” stated Prashant Samant, CEO and co-founder of Akido. “ScopeAI removes the administrative weight of the visit and supports investigative intake, so physicians can spend their time on what only a human doctor can do.” As Akido scales Akido Medical across its multi-state clinic footprint, it provides a functional blueprint for how AI-native health systems will redefine medical access and physician practice nationwide.
Reader Interactions